{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:07:37Z","timestamp":1789024057747,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This systematic review aimed to assess the clinical effectiveness and safety profile of baloxavir marboxil for managing influenza in pediatric populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review has been registered on the INPLASY platform (INPLASY2025110063). Designed in accordance with the PRISMA 2020 guidelines, we searched four major biomedical databases (PubMed, Embase, Web of Science, Cochrane Library) covering publications from January 1, 2015, to January 30, 2025. Eligibility criteria encompassed both randomized controlled trials and observational cohort studies evaluating this antiviral agent in children with laboratory-confirmed influenza. Methodological rigor was appraised using the Cochrane Collaboration's risk of bias instrument for randomized controlled trials (RCTs) and the Newcastle-Ottawa Quality Assessment Scale for cohort studies. Statistical synthesis was conducted using RevMan 5.3 software (Version 5.3.5) with metafor package implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our analysis incorporated 12 clinical investigations involving a total of 4,586 patients. A random-effects model meta-analysis demonstrated that, compared to neuraminidase inhibitors (oseltamivir, zanamivir, peramivir, laninamivir), baloxavir marboxil achieved accelerated resolution of febrile symptoms (MD\u2009=\u2009\u221213.16\u2005h, 95% CI: \u221219.16 to \u22127.15,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.0001). Subgroup analyses stratified by viral subtype demonstrated consistent therapeutic advantages in influenza A infections (random-effects model, MD\u2009=\u2009\u22129.40\u2005h, 95% CI: \u221218.31 to \u22120.49,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.04), particularly regarding time to symptom alleviation (fixed-effect model, MD\u2009=\u2009\u22128.50 hours, 95% CI: \u221213.14 to \u22123.86,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0003). Safety assessments indicated a 59% reduction in drug-related adverse events relative to oseltamivir (fixed-effect model, OR 0.41, 95% CI 0.31\u20130.56;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001), while total adverse event rates showed comparable incidence between treatment arms (fixed-effect model, OR\u2009=\u20090.85, 95% CI: 0.69\u20131.05,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.14).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest baloxavir marboxil demonstrates faster fever resolution and a favorable safety profile in pediatric influenza management. However, continuous monitoring for baloxavir-resistant mutations (such as PA\/I38T) in the pediatric population is warranted. Furthermore, confirmation through large-scale multicenter trials with extended follow-up periods remains warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1733111","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T06:37:19Z","timestamp":1767595039000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Comprehensive evaluation of therapeutic effectiveness and safety profiles of baloxavir marboxil for managing influenza virus infection in pediatric populations: a systematic review with pooled meta-analytic data"],"prefix":"10.3389","volume":"13","author":[{"given":"Yishu","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13054-019-2539-x","article-title":"Influenza virus-related critical illness: pathophysiology and epidemiology","volume":"23","author":"Kalil","year":"2019","journal-title":"Crit Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.vaccine.2019.11.040","article-title":"An assessment of parental knowledge, attitudes, and beliefs regarding influenza vaccination","volume":"38","author":"Goss","year":"2020","journal-title":"Vaccine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/pathogens8040265","article-title":"The importance of vaccinating children and pregnant women against influenza virus infection","volume":"8","author":"Misra","year":"2019","journal-title":"Pathogens"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0004022","DOI":"10.1128\/cmr.00040-22","article-title":"Antiviral approaches against influenza virus","volume":"36","author":"Kumari","year":"2023","journal-title":"Clin Microbiol Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/microorganisms11010183","article-title":"Influenza treatment: limitations of antiviral therapy and advantages of drug combination therapy","volume":"11","author":"Batool","year":"2023","journal-title":"Microorganisms"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s40265-018-0981-8","article-title":"Peramivir: a review in uncomplicated influenza","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.2147\/dddt.s46654","article-title":"Safety and efficacy of peramivir for influenza treatment","volume":"8","author":"Hata","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e20160109","DOI":"10.1542\/peds.2016-0109","article-title":"Inhaled laninamivir octanoate as prophylaxis for influenza in children","volume":"138","author":"Nakano","year":"2016","journal-title":"Pediatrics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"g2675","DOI":"10.1136\/bmj.g2675","article-title":"Cochrane review questions effectiveness of neuraminidase inhibitors","volume":"348","author":"Torjesen","year":"2014","journal-title":"Br Med J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"j2841","DOI":"10.1136\/bmj.j2841","article-title":"WHO downgrades oseltamivir on drugs list after reviewing evidence","volume":"357","author":"Kmietowicz","year":"2017","journal-title":"Br Med J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/ph15010028","article-title":"Baloxavir marboxil: an original new drug against influenza","volume":"15","author":"Dufrasne","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/cid\/ciz908","article-title":"Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes","volume":"71","author":"Hirotsu","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1097\/inf.0000000000002747","article-title":"Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2)","volume":"39","author":"Baker","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/inf.0000000000004062","article-title":"Safety and efficacy of baloxavir marboxil in influenza-infected children 5\u201311 years of age: a post hoc analysis of a phase 3 study","volume":"42","author":"Baker","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"105092","DOI":"10.1016\/j.antiviral.2021.105092","article-title":"Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: a Japanese multicenter study in the 2019\u20132020 influenza season","volume":"192","author":"Chong","year":"2021","journal-title":"Antiviral Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1418321","DOI":"10.3389\/fped.2024.1418321","article-title":"Safety and effectiveness of baloxavir marboxil and oseltamivir for influenza in children: a real-world retrospective study in China","volume":"12","author":"Ge","year":"2024","journal-title":"Front Pediatr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/s1473-3099(20)30004-9","article-title":"Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Ison","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/ped.13855","article-title":"Effectiveness of baloxavir marboxil against influenza in children","volume":"61","author":"Kakuya","year":"2019","journal-title":"Pediatr Int"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e15169","DOI":"10.1111\/ped.15169","article-title":"Clinical effectiveness of baloxavir marboxil against influenza in three seasons","volume":"64","author":"Kakuya","year":"2022","journal-title":"Pediatr Int"},{"key":"B21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12879-023-08140-z","article-title":"Factors associated with viral RNA shedding and evaluation of potential viral infectivity at returning to school in influenza outpatients after treatment with baloxavir marboxil and neuraminidase inhibitors during 2013\/2014\u20132019\/2020 seasons in Japan: an observational study","volume":"23","author":"Li","year":"2023","journal-title":"BMC Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59091543","article-title":"Early fever resolution in early childhood influenza treated with baloxavir marboxil: a retrospective study compared to those with oseltamivir","volume":"59","author":"Nezu","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1248\/bpb.b20-00543","article-title":"A comparison of the frequency of prescription and pharmacy revisits between baloxavir marboxil and neuraminidase inhibitors in influenza-infected pediatric patients during the 2019\u20132020 influenza season","volume":"43","author":"Norikoshi","year":"2020","journal-title":"Biol Pharm Bull"},{"key":"B24","doi-asserted-by":"publisher","first-page":"104951","DOI":"10.1016\/j.antiviral.2020.104951","article-title":"Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018\u20132019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions","volume":"183","author":"Saito","year":"2020","journal-title":"Antiviral Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"105310","DOI":"10.1016\/j.antiviral.2022.105310","article-title":"Duration of fever and symptoms in influenza-infected children treated with baloxavir marboxil during the 2019\u20132020 season in Japan and detection of influenza virus with the PA E23K substitution","volume":"201","author":"Wagatsuma","year":"2022","journal-title":"Antiviral Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jiac.2020.04.014","article-title":"Safety and effectiveness of baloxavir marboxil for the treatment of influenza in Japanese clinical practice: a postmarketing surveillance of more than 3000 patients","volume":"26","author":"Nakazawa","year":"2020","journal-title":"J Infect Chemother"},{"key":"B27","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/inf.0000000000002748","article-title":"Baloxavir marboxil 2% granules in Japanese children with influenza: an open-label phase 3 study","volume":"39","author":"Yokoyama","year":"2020","journal-title":"Pediatr Infect Dis J"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1733111\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T06:37:19Z","timestamp":1767595039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1733111\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":27,"alternative-id":["10.3389\/fped.2025.1733111"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1733111","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1733111"}}